(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead Sciences (NASDAQ:GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

U.S. President Joe Biden said on Wednesday (January 15) that Israel and Hamas have reached a ceasefire and hostage deal that ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Biotech dealmaking is back — but smaller and more intimate. Deals disclosed in the early days of the new year indicate that ...

Democratic-led states defend a Biden rule for DACA immigrants' healthcare, US regulators propose reducing nicotine in ...

A man was carjacked while pumping gas in the middle of the day, and now police in Huntersville are searching for the suspect.

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91 which represents a slight increase of $1.06 or 1.18% from the prior close of $89.94. The stock opened at $90.59 and touched ...

Gilead Sciences, Inc. ("Gilead") (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or v ...

Let’s talk about my PFWA awards ballot, featuring tough decisions at MVP, defensive player of the year and defensive rookie ...